Stallergenes Greer, a biopharmaceutical laboratory specializing in allergen immunotherapy (ITA), announces the results of its real-life study, EfficAPSI, evaluating the effects of its sublingual ITA solutions on the onset and progression of asthma in patients with allergic rhinitis, were published in the journal The Lancet Regional Health-Europe. This article, already published online (https://doi.org/10.1016/j.lanepe.2024.100915), will soon be available in print.
This longitudinal and retrospective real-life pharmaco-epidemiological study evaluated, over a period of 9 years, more than 440,000 patients: more than 110,000 patients suffering from allergic rhinitis, with or without asthma, treated with sublingual solutions from Stallergenes Greer and symptomatic medications; compared to more than 330,000 patients suffering from allergic rhinitis, with or without asthma, treated only with symptomatic medications.
The primary objective of the study was to evaluate the real-world effects of Stallergenes Greer sublingual solutions on preventing the onset and worsening of asthma in patients with allergic rhinitis. The results of the study are consistent across all age categories (from 5 years), allergens and evaluation criteria.
EfficAPSI showed, in patients treated with Stallergenes Greer sublingual solutions and symptomatic medications, compared to patients treated with symptomatic medications only:
- a 36% reduction in the risk of new asthma attacks across the entire cohort*;
- a 38% reduction in the risk of developing asthma in patients without pre-existing asthma;
- a reduction by a third in the intensification of treatment recommended within the framework of the Global Initiative for Asthma (GINA), in patients suffering from pre-existing asthma, which demonstrates the effect of sublingual solutions in preventing the worsening of asthma.
“I am delighted to communicate this large EfficAPSI study to the medical community through its publication in The Lancet Regional Health-Europe. EfficAPSI confirms the role of sublingual solutions in improving asthma management. Its results provide important data on the relevance of sublingual solutions as an etiological treatment allowing personalized care, adapted to the unique needs of each patient, and offering better clinical results,” declares Professor Pascal Demoly, Head of the department. of pulmonology, allergology and thoracic oncology at Montpellier University Hospital (France), President of the French Society of Allergology, and member of the study’s scientific committee.
“It is essential to study the effects of allergen immunotherapy on the onset and progression of asthma. Through this real-life EfficAPSI study, Stallergenes Greer is proud to provide scientific evidence and valuable insight into allergy treatment. We remain focused on developing solutions to change disease progression, powered by robust clinical data, to redefine the management of respiratory diseases and improve the quality of life of people suffering from allergies.” , says Dr. Elena Rizova, Medical Director of Stallergenes Greer.
By demonstrating their benefit with regard to the onset and worsening of asthma, Stallergenes Greer’s sublingual solutions confirm their utility in public health. Stallergenes Greer intends to intensify the use of this approach in real life to strengthen the level of evidence of the benefits of its sublingual ITA treatments. Other criteria are currently being evaluated and will be published later.
Source and visual: Stallergenes Greer
*combined score
________________________________
1 Demoly P, Molimard M, Bergmann JF, et al. Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study). Lancet Reg Health Eur. 2024.
2 Demoly P, Corren J, Creticos P, et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. J Allergy Clin Immunol. 2021;147(3):1020-1030.e10
3 Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160.
4 Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–8
5 Linneberg A., Henrik Nielsen N., Frolund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002 Nov;57(11):1048-1052.
6 Shin JW, Sue JH, Song TW, et al. Atopy and house dust mite sensitization as risk factors for asthma in children. Yonsei Med J.2005;46:629-634.
7 Hankin CS, Cox L., Lang D., et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010 Jan;104(1):79-85
